Weekly Top News - Psoriasis

FYB202 (ustekinumab biosimilar) /Formycon, Aristo Pharma
VESPUCCI:A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov)- Oct 20, 2020 - P3; N=392; Recruiting; Sponsor: Bioeq GmbH 

Cosentyx(secukinumab) / Novartis
IQVIA on changes to the draft November reimbursement lists [Google translation](Polityka Zdrowotna) - Oct 21, 2020 -"From November, the drug Kalydeco (ivacaftorum) will be reimbursed under the drug program 'Treatment of cystic fibrosis'....From November 1, 2020,Cosentyx (secukinumab) will not be reimbursed under drug programs: treatment of aggressive psoriatic arthritis (PsA), treatment of severe, active ankylosing spondylitis (AS), treatment of moderate to severe plaque psoriasis. At the same time, it was the only medicinal product containing this active substance covered by the refund." 

benvitimod(DMVT-505) / Roivant, Japan Tobacco
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) (clinicaltrials.gov) - Oct 19, 2020 - P3; N=515;Completed; Sponsor: Dermavant Sciences GmbH; Active, not recruiting -->Completed 

benvitimod(DMVT-505) / Roivant, Japan Tobacco
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) (clinicaltrials.gov) - Oct 19, 2020 - P3; N=510;Completed; Sponsor: Dermavant Sciences GmbH; Active, not recruiting -->Completed 

BI730357 / Boehringer Ingelheim
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is (clinicaltrials.gov)- Oct 22, 2020 - P2; N=270; Recruiting; Sponsor: Boehringer Ingelheim; N=180--> 270 

EDP1815/ Evelo Biosci
A Phase2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis (clinicaltrials.gov)- Oct 26, 2020 - P2; N=225; Recruiting; Sponsor: Evelo Biosciences, Inc. 

Otezla(apremilast) / Amgen
EMBRACE:A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life (clinicaltrials.gov)- Oct 19, 2020 - P4; N=255; Active, not recruiting; Sponsor: Amgen; Recruiting--> Active, not recruiting 

‍